Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event

Taysha Gene Therapies, Inc. engages Rettsyndrome community at Patient First event
Taysha Gene Therapies joins Patient First

Taysha Gene Therapies, Inc. participated in a Patient First event facilitated by Catalent and the International Rettsyndrome Foundation.

The company expressed appreciation for the collaboration, highlighting the importance of direct engagement with the Rettsyndrome community. This interaction aims to strengthen shared commitment to advancing therapies and support for individuals affected by the condition.

Taysha Gene Therapies is scheduled to report first quarter 2026 earnings next week. The company will also deliver a corporate update as part of its earnings release. Additional financial and operational details are available in the earnings announcement preview.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.